Anti-CD83 mAb, 3C12C and its toxin conjugate, kill CD83+ Hodgkin lymphoma cells in vitro as presented by Ziduo Li et al at the 23rd Congress of European Hematology Association (EHA) (Free EHA Whitepaper) (Abstracts, EHA (Free EHA Whitepaper) 2018, The European Hematology Association (EHA) (Free EHA Whitepaper), JUN 11, 2018, View Source [SID1234527259]). No toxicity was observed in 3C12C dose-escalation non-human primates study. These data establish CD83 as a potential biomarker and therapeutic target in Hodgkin lymphoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!